Concepedia

Publication | Closed Access

An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.

33

Citations

0

References

2004

Year

Heather McDonald, Margaret Hux, Marc Brisson, Lisa Bernard, J. Curtis Nickel
PubMed

Abstract

Combination therapy is cost-effective compared to doxazosin with cost-utility ratios under 40,000 dollars/QALY across a wide range of scenarios. The cost-effectiveness of combination therapy increases as serum PSA level increases.